A Prospective, Open-Label, Multicenter Study Comparing Lymphoseek and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping

Trial Profile

A Prospective, Open-Label, Multicenter Study Comparing Lymphoseek and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Malignant melanoma; Rhabdomyosarcoma; Solid tumours
  • Focus Diagnostic use
  • Sponsors Cardinal Health; Navidea Biopharmaceuticals
  • Most Recent Events

    • 21 Sep 2017 Planned End Date changed from 1 Sep 2017 to 1 Jun 2021.
    • 21 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jun 2021.
    • 27 Jun 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top